These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7438379)

  • 1. Proceedings of the Workshop on platelet-active drugs in the secondary prevention of cardiovascular events. February 20-21, 1980, National Institutes of Health, Bethesda, Maryland.
    Circulation; 1980 Dec; 62(6 Pt 2):V1-135. PubMed ID: 7438379
    [No Abstract]   [Full Text] [Related]  

  • 2. Platelet-active drugs in the secondary prevention of cardiovascular events: an overview.
    Weiss HJ
    Circulation; 1980 Dec; 62(6 Pt 2):V41-3. PubMed ID: 7002351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proceedings of the National Conference on School Health Education Research in the Heart, Lung, and Blood Areas. September 15-16, 1983, National Institutes of Health, Bethesda, Maryland.
    J Sch Health; 1984; 54(6):1-88. PubMed ID: 6565114
    [No Abstract]   [Full Text] [Related]  

  • 4. Proceedings of the National Conference on School Health Education Research in the Heart, Lung, and Blood Areas. September 15-16, 1983, National Institutes of Health, Bethesda, Maryland.
    Health Educ; 1984; 15(4):1-88. PubMed ID: 6444025
    [No Abstract]   [Full Text] [Related]  

  • 5. Should we monitor platelet function during antiplatelet therapy?
    Hjemdahl P
    Heart; 2008 Jun; 94(6):685-7. PubMed ID: 18480343
    [No Abstract]   [Full Text] [Related]  

  • 6. Translational therapeutics at the platelet vascular interface. Introduction.
    FitzGerald GA
    Arterioscler Thromb Vasc Biol; 2008 Mar; 28(3):s3-4. PubMed ID: 18296587
    [No Abstract]   [Full Text] [Related]  

  • 7. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease.
    Maree AO; Curtin RJ; Dooley M; Conroy RM; Crean P; Cox D; Fitzgerald DJ
    J Am Coll Cardiol; 2005 Oct; 46(7):1258-63. PubMed ID: 16198840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacology of platelet activation-inhibitory drugs.
    Rao GH; Rao AT
    Indian J Physiol Pharmacol; 1994 Apr; 38(2):69-84. PubMed ID: 8063366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring oral antiplatelet therapy: is it justified?
    Ang L; Mahmud E
    Ther Adv Cardiovasc Dis; 2008 Dec; 2(6):485-96. PubMed ID: 19124443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy.
    Christie DJ; Kottke-Marchant K; Gorman RT
    Platelets; 2008 Mar; 19(2):104-10. PubMed ID: 17852773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspirin resistance: what, why and when?
    Shantsila E; Watson T; Lip GY
    Thromb Res; 2007; 119(5):551-4. PubMed ID: 17010411
    [No Abstract]   [Full Text] [Related]  

  • 12. Current concepts in antiplatelet therapy for cardiovascular disease.
    Martinez A
    JAAPA; 2004 Mar; 17(3):16-20, 23-4; quiz 51-2. PubMed ID: 15314880
    [No Abstract]   [Full Text] [Related]  

  • 13. Congenital urinary tract obstruction: Proceedings of the State-Of-The-Art Strategic Planning Workshop-National Institutes of Health, Bethesda, Maryland, USA, 11-12 March 2002.
    Chevalier RL; Peters CA
    Pediatr Nephrol; 2003 Jun; 18(6):576-606. PubMed ID: 12720078
    [No Abstract]   [Full Text] [Related]  

  • 14. Antiplatelet agents: current drugs and future trends.
    Messmore HL; Jeske WP; Wehrmacher W; Coyne E; Mobarhan S; Cho L; Leya FS; Moran JF
    Hematol Oncol Clin North Am; 2005 Feb; 19(1):87-117, vi. PubMed ID: 15639110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance.
    Siller-Matula J; Schrör K; Wojta J; Huber K
    Thromb Haemost; 2007 Mar; 97(3):385-93. PubMed ID: 17334505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scientific and therapeutic advances in antiplatelet therapy.
    Bhatt DL; Topol EJ
    Nat Rev Drug Discov; 2003 Jan; 2(1):15-28. PubMed ID: 12509756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do polyunsaturated fatty acids behave like an endogenous "polypill"?
    Das UN
    Med Hypotheses; 2008; 70(2):430-4. PubMed ID: 17624683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Symposium on cellular resistance to anticancer drugs. National Institutes of Health, Bethesda, Maryland, February 25, 1983.
    Cancer Treat Rep; 1983 Oct; 67(10):855-931. PubMed ID: 6627235
    [No Abstract]   [Full Text] [Related]  

  • 20. Platelet dysfunction in central obesity.
    Anfossi G; Russo I; Trovati M
    Nutr Metab Cardiovasc Dis; 2009 Jul; 19(6):440-9. PubMed ID: 19346117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.